Neumora Therapeutics (NMRA) Other Accumulated Expenses (2022 - 2026)
Neumora Therapeutics' (NMRA) quarterly Other Accumulated Expenses came in at $736000.0 in Q1 2026, up 79.95% year-on-year from $409000.0 in Q1 2025, and up 1.66% quarter-over-quarter from $724000.0 in Q4 2025.
Neumora Therapeutics (NMRA) Other Accumulated Expenses (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $736000.0 for Q1 2026.
- On a quarterly basis, Other Accumulated Expenses rose 79.95% year-over-year to $736000.0 in Q1 2026; TTM through Mar 2026 was $736000.0, a 79.95% increase from a year earlier, with the FY2025 full-year figure at $724000.0, up 122.09% from the prior year.
- Other Accumulated Expenses rose to $736000.0 in Q1 2026 per NMRA's latest filing, from $724000.0 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $750000.0 in Q4 2023 and bottomed at $326000.0 in Q4 2024.
- The 5-year median for Other Accumulated Expenses is $429000.0 (2025), against an average of $493916.7.
- Across the five-year window, Other Accumulated Expenses slumped 56.53% in 2024 and surged 122.09% in 2025, its largest moves.
- Year by year, Other Accumulated Expenses stood at $408000.0 in 2022, then soared by 83.82% to $750000.0 in 2023, then slumped by 56.53% to $326000.0 in 2024, then jumped by 122.09% to $724000.0 in 2025, then grew by 1.66% to $736000.0 in 2026.
- Per Business Quant, the three latest NMRA Other Accumulated Expenses figures stand at $736000.0 (Q1 2026), $724000.0 (Q4 2025), and $449000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Neumora Therapeutics | 280.60 Mn | 280.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 736,000.00 |
| Dec 31, 2025 | 724,000.00 |
| Sep 30, 2025 | 449,000.00 |
| Jun 30, 2025 | 450,000.00 |
| Mar 31, 2025 | 409,000.00 |
| Dec 31, 2024 | 326,000.00 |
| Sep 30, 2024 | 392,000.00 |
| Jun 30, 2024 | 366,000.00 |
| Mar 31, 2024 | 542,000.00 |
| Dec 31, 2023 | 750,000.00 |
| Sep 30, 2023 | 375,000.00 |
| Dec 31, 2022 | 408,000.00 |